Monoamine Oxidase Inhibitors Prevent Glucose-Dependent Energy Production, Proliferation and Migration of Bladder

Jessica Resta1, Yohan Santin1, Mathieu Roumiguié2

  • 1Institute of Metabolic and Cardiovascular Diseases (I2MC), INSERM, Toulouse University, 31000 Toulouse, France.

Insights

Monoamine oxidases (MAOs) drive bladder cancer growth by increasing reactive oxygen species (ROS) and promoting glucose metabolism. Inhibiting MAOs reduces tumor cell proliferation, migration, and energy production.

Area of Science:

  • Oncology
  • Biochemistry
  • Metabolic pathways

Background:

  • Bladder cancer exhibits high recurrence and metastasis rates, necessitating novel therapeutic targets.
  • Cancer cells reprogram metabolism, often favoring aerobic glycolysis, to meet high energy demands.
  • Reactive oxygen species (ROS) are crucial in cancer development, but their sources in bladder cancer are unclear.

Purpose of the Study:

  • To investigate the role of monoamine oxidases (MAOs) and their ROS production in bladder cancer.
  • To evaluate the therapeutic potential of MAO inhibition in bladder cancer treatment.

Main Methods:

  • Analysis of MAO-A and MAO-B expression in human urothelial tumor explants and AY27 bladder cancer cells.
  • Assessment of MAO inhibition effects on ROS levels, cell cycle, proliferation, and motility.
  • Utilized a catalytically inactive MAO-A mutant to confirm the role of ROS in tumorigenesis.
  • Investigated the impact of MAO inhibition on glucose metabolism, including glycolysis and oxidative phosphorylation.

Main Results:

  • Both MAO-A and MAO-B isoforms were expressed in bladder cancer cells.
  • Selective MAO-A or MAO-B inhibition reduced ROS accumulation, cell proliferation, and cell cycle progression.
  • MAO-A inhibition specifically decreased cancer cell motility.
  • MAO-dependent ROS production was essential for proliferation and migration, as shown by the inactive MAO-A mutant.
  • MAO inhibition significantly reduced glycolysis and oxidative phosphorylation, impacting glucose transporter (GLUT1) and hexokinase 2 (HK2) expression.

Conclusions:

  • Bladder cancer cells rely on a glucose-dependent metabolic phenotype regulated by MAO-driven oxidative stress.
  • MAO-A and MAO-B are key players in bladder cancer progression through ROS generation.
  • Targeting MAOs represents a promising therapeutic strategy for bladder cancer by disrupting metabolic reprogramming.

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
238
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
267
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.5K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
534
Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.2K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
234